Decoy Therapeutics Inc.
DCOY· Nasdaq
DCOYDecoy Therapeutics Inc.
Filed Mar 25, 2022 · 10-K · 84 days after period end · 0001615219-22-000028
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018 |
|---|---|---|---|---|
| Revenue | $0.00 | $1.48M | $1.04M | $163.07K |
| Net Income | -$4.10M | -$1.77M | -$1.88M | -$2.01M |
| EPS Diluted | — | — |
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
| — |
| -$0.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2021 · filed Mar 25, 2022 · 84 d after period end
